Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

Abstract Background Although docetaxel-based chemohormonal therapy (CHT) is one of the standard treatments for castration-resistant prostate cancer (CRPC), pertinent biomarkers and precise mechanisms involved in the resistance for CHT for CRPC remain unknown. We investigated the relationship between...

Full description

Bibliographic Details
Main Authors: Yoshinori Matsuda, Shintaro Narita, Taketoshi Nara, Huang Mingguo, Hiromi Sato, Atsushi Koizumi, Sohei Kanda, Kazuyuki Numakura, Mitsuru Saito, Takamitsu Inoue, Yuko Hiroshima, Hiroshi Nanjo, Shigeru Satoh, Norihiko Tsuchiya, Tomonori Habuchi
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Cancer
Subjects:
YAP1
Residual cancer
Neoadjuvant chemohormonal therapy
Docetaxel
Prostate cancer
High-risk
Online Access:http://link.springer.com/article/10.1186/s12885-020-06844-y

Internet

http://link.springer.com/article/10.1186/s12885-020-06844-y

Similar Items